| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cardiac Resynchronization Therapy (CRT) in Heart Failure—A Model to Assess the Economic Value of this New Medical Technology
|
Banz, Kurt
|
|
2005
|
8 |
Supplement 1 |
p. 128-139
12 p.
|
artikel
|
| 2 |
CN3 HEALTH ECONOMIC EVALUATION BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
|
Moeremans, K
|
|
2005
|
8 |
Supplement 1 |
p. A21-A22
nvt p.
|
artikel
|
| 3 |
Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling Study
|
Feenstra, Talitha L.
|
|
2005
|
8 |
Supplement 1 |
p. 178-190
13 p.
|
artikel
|
| 4 |
Cost-Effectiveness of Recombinant Human Erythropoietin for Reducing Red Blood Cells Transfusions in Critically Ill Patients
|
MacLaren, Robert
|
|
2005
|
8 |
Supplement 1 |
p. 105-116
12 p.
|
artikel
|
| 5 |
Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective
|
Benner, Joshua S.
|
|
2005
|
8 |
Supplement 1 |
p. 618-628
11 p.
|
artikel
|
| 6 |
CS8 ECONOMIC EVALUATION OF ONDANSETRON VERSUS DIMENHYDRINATE FOR PREVENTION OF POSTOPERATIVE VOMITING IN CHILDREN
|
Piwko, C
|
|
2005
|
8 |
Supplement 1 |
p. 254-255
2 p.
|
artikel
|
| 7 |
CS3 IMPACT OF ESTIMATION TECHNIQUE ON MEDICAL COST ESTIMATES FOR OVERACTIVE BLADDER TREATMENTS
|
Nitz, NM
|
|
2005
|
8 |
Supplement 1 |
p. 249-
1 p.
|
artikel
|
| 8 |
CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME
|
Ruciñski, P
|
|
2005
|
8 |
Supplement 1 |
p. A2-
1 p.
|
artikel
|
| 9 |
CV4 DISCRETE EVENT SIMULATION OF THE ECONOMIC CONSEQUENCES OF ADDING MANAGED VENTRICULAR PACING MODE (DDDR-MVP) TO A STANDARD DUAL CHAMBER PACEMAKER (DDDR) IN FRANCE
|
Deniz, HB
|
|
2005
|
8 |
Supplement 1 |
p. A3-
1 p.
|
artikel
|
| 10 |
DB6 COMPARISON OF THE COST-EFFECTIVENESS FOR BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR+ INSULIN ASPART OR HUMAN INSULIN-BASED REGIMENS IN THE NETHERLANDS
|
Wj, Valentine
|
|
2005
|
8 |
Supplement 1 |
p. 255-
1 p.
|
artikel
|
| 11 |
DB2 ECONOMIC CONSEQUENCES OF CHOICE OF DIABETES THERAPY IN A MEDICAID POPULATION
|
Kalsekar, I
|
|
2005
|
8 |
Supplement 1 |
p. 250-
1 p.
|
artikel
|
| 12 |
Economic Burden of Patients with Anemia in Selected Diseases
|
Ershler, William B.
|
|
2005
|
8 |
Supplement 1 |
p. 629-638
10 p.
|
artikel
|
| 13 |
Effect of Outpatient Treatment of Febrile Neutropenia on the Risk Threshold for the Use of CSF in Patients with Cancer Treated with Chemotherapy
|
Cosler, Leon E.
|
|
2005
|
8 |
Supplement 1 |
p. 47-52
6 p.
|
artikel
|
| 14 |
Excess Mortality, Length of Stay, and Costs Associated with Serious Fungal Infections among Elderly Cancer Patients: Findings from Linked SEER-Medicare Data
|
Menzin, Joseph
|
|
2005
|
8 |
Supplement 1 |
p. 140-148
9 p.
|
artikel
|
| 15 |
Growth and Quality of the Cost–Utility Literature, 1976–2001
|
Neumann, Peter J.
|
|
2005
|
8 |
Supplement 1 |
p. 3-9
7 p.
|
artikel
|
| 16 |
Health and Economic Consequences of Sevelamer Use for Hyperphosphatemia in Patients on Hemodialysis
|
Huybrechts, Krista F.
|
|
2005
|
8 |
Supplement 1 |
p. 549-561
13 p.
|
artikel
|
| 17 |
Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among Outpatient Pharmacy Consumers
|
Atkinson, Mark J.
|
|
2005
|
8 |
Supplement 1 |
p. S9-S24
16 p.
|
artikel
|
| 18 |
HP8 FINANCIAL IMPACT OF A PRIOR-AUTHORIZATION RESTRICTION FOR PIMECROLIMUS 1% CREAM IN THE TREATMENT OF ATOPIC DERMATITIS
|
Mahajan, S
|
|
2005
|
8 |
Supplement 1 |
p. 243-
1 p.
|
artikel
|
| 19 |
HP8 PATIENT CHARACTERICS, GLYCEMIC CONTROL, AND THE USE OF ANTIDIABETIC AGENTS AMONG INDIVIDUALS DIAGNOSED WITH TYPE-2 DIABETES: EVIDENCE FROM THE UK
|
Secnik, K
|
|
2005
|
8 |
Supplement 1 |
p. A12-A13
nvt p.
|
artikel
|
| 20 |
MS2 CARDIOVASCULAR RISK FACTORS AT BASELINE IN USERS OF COXIBS COMPARED TO USERS OF NSAIDS
|
De Jong, RB
|
|
2005
|
8 |
Supplement 1 |
p. 241-
1 p.
|
artikel
|
| 21 |
Obesity, Survival, and Hospital Costs—Findings from a Screening Project in Sweden
|
Borg, Sixten
|
|
2005
|
8 |
Supplement 1 |
p. 562-571
10 p.
|
artikel
|
| 22 |
PAL3 WILLINGNESS TO PAY FOR INTRANASAL CORTICOSTEROID THERAPY:THE IMPORTANCE OF SENSORY ATTRIBUTES
|
Kleinman, L
|
|
2005
|
8 |
Supplement 1 |
p. 339-340
2 p.
|
artikel
|
| 23 |
PAR10 ARE THEY RELEVANT? A CRITICAL EVALUATION OF THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH CORE SETS FOR OSTEOARTHRITIS FROM THE PERSPECTIVE OF PATIENTS WITH KNEE OSTEOARTHRITIS IN SINGAPORE
|
Xie, F
|
|
2005
|
8 |
Supplement 1 |
p. A27-
1 p.
|
artikel
|
| 24 |
PAR13 THE DIRECT MEDICAL COST OF RHEUMATOID ARTHRITIS IN HONG KONG
|
Lee, VWY
|
|
2005
|
8 |
Supplement 1 |
p. A27-A28
nvt p.
|
artikel
|
| 25 |
PAR11 THE IMPACT OF DEPRESSION ON RHEUMATOID ARTHRITIS PATIENT QUALITY OF LIFE
|
Zhang, L
|
|
2005
|
8 |
Supplement 1 |
p. 343-
1 p.
|
artikel
|
| 26 |
PAS9 CHOOSING AMONG DIFFERENT TYPES OF MATCHING TECHNIQUES
|
Baser, O
|
|
2005
|
8 |
Supplement 1 |
p. 260-
1 p.
|
artikel
|
| 27 |
PAS6 IMPACT OF ASTHMA KNOWLEDGE ON HEALTH OUTCOMES IN PEDIATRIC PATIENTS
|
Suksomboon, N
|
|
2005
|
8 |
Supplement 1 |
p. 259-
1 p.
|
artikel
|
| 28 |
PAS7 THE HUMAN IMPACT OF SEVERE PERSISTENT ALLERGIC ASTHMA: RESULTS FROM A MULTINATIONAL STUDY
|
Turk, F
|
|
2005
|
8 |
Supplement 1 |
p. A32-
1 p.
|
artikel
|
| 29 |
Patterns and Effectiveness of Lipid-Lowering Therapies in a Managed Care Environment
|
Meyer, Jay W.
|
|
2005
|
8 |
Supplement 1 |
p. 601-612
12 p.
|
artikel
|
| 30 |
PCN32 COST-EFFECTIVENESS ANALYSIS OF LETROZOLE VERSUS TAMOXIFEN AS INITIAL ADJUVANT THERAPY IN HORMONE-RECEPTOR POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER IN THE UK
|
Karnon, J
|
|
2005
|
8 |
Supplement 1 |
p. A43-
1 p.
|
artikel
|
| 31 |
PCN29 PER-PATIENT COST OF HOSPITAL CARE FOR ADVANCED BREAST CANCER IN THE UK BASED ON A PATIENT-LEVEL RESOURCE UTILISATION DATASET
|
Wolowacz, S
|
|
2005
|
8 |
Supplement 1 |
p. A42-
1 p.
|
artikel
|
| 32 |
PCN15 PHARMACOECONOMIC ANALYSIS OF EXEMESTANE VERSUS TAMOXIFEN AS ADJUVANT THERAPY FOR PATIENTS WITH EARLY-STAGE ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
|
Gil, JM
|
|
2005
|
8 |
Supplement 1 |
p. A37-A38
nvt p.
|
artikel
|
| 33 |
PCN13 SURVIVAL AND COST FOLLOWING BREAST CANCER RECURRENCE: ESTIMATES FROM SEER-MEDICARE DATA
|
Thompson, D
|
|
2005
|
8 |
Supplement 1 |
p. 347-
1 p.
|
artikel
|
| 34 |
PCN16 THE CLINICAL OUTCOMES AND COSTS OF TREATING ONCOLOGY PATIENTS FOR SEVERE SEPSIS
|
King, KM
|
|
2005
|
8 |
Supplement 1 |
p. 348-
1 p.
|
artikel
|
| 35 |
PCN46 WHAT ARE THE PSYCHOSOCIAL CONSEQUENCES OF AN ABNORMAL SCREENING-MAMMOGRAPHY?
|
Brodersen, J
|
|
2005
|
8 |
Supplement 1 |
p. A47-
1 p.
|
artikel
|
| 36 |
PCV33 A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN FOUR EUROPEAN COUNTRIES
|
Lamotte, M
|
|
2005
|
8 |
Supplement 1 |
p. A98-A99
nvt p.
|
artikel
|
| 37 |
PCV19 A LITERATURE REVIEW OF PATIENT-REPORTED OUTCOMES (PRO) USED IN ATRIAL FIBRILLATION
|
Staniek, V
|
|
2005
|
8 |
Supplement 1 |
p. A94-
1 p.
|
artikel
|
| 38 |
PCV45 ANTIHYPERTENSIVE THERAPY AFTER ALLHAT: ARE MORE PATIENTS STARTING WITH DIURETICS?
|
Petrilla, AA
|
|
2005
|
8 |
Supplement 1 |
p. 274-
1 p.
|
artikel
|
| 39 |
PCV48 ASSESSMENT OF MAXIMUM LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN) IN SPAIN
|
Davies, G
|
|
2005
|
8 |
Supplement 1 |
p. A103-
1 p.
|
artikel
|
| 40 |
PCV2 COST-EFFECTIVENESS OF AN INTENSIVE TREATMENT WITH 80MGATORVASTATINVS 40 MG PRAVASTATIN IN ACUTE CORONARY SYNDROME: AN ECONOMIC EVALUATION BASED ON THE PROVE-IT (PRAVASTATIN ORATORVASTATIN EVALUATION AND INFECTION THERAPY)
|
F Bobadilla, J
|
|
2005
|
8 |
Supplement 1 |
p. A89-
1 p.
|
artikel
|
| 41 |
PCV28 COST-UTILITY ANALYSIS FOR STATINS IN MEXICO
|
Mould Quevedo, JF
|
|
2005
|
8 |
Supplement 1 |
p. 269-
1 p.
|
artikel
|
| 42 |
PCV82 COST-UTILITY OF CILOSTAZOL FOR THE TREATMENT OF INTERMITTENT CLAUDICATION IN SCOTLAND
|
Ratcliffe, A
|
|
2005
|
8 |
Supplement 1 |
p. A113-A114
nvt p.
|
artikel
|
| 43 |
PCV31 DOES PLAN DESIGN AFFECT THERAPY ADHERENCE FOR CHRONIC CONDITIONS?
|
Matlin, OS
|
|
2005
|
8 |
Supplement 1 |
p. 270-
1 p.
|
artikel
|
| 44 |
PCV92 HEALTH RELATED QUALITY OF LIFE (QOL) IN PATIENTS RECEIVING VITAMIN K ANTAGONISTS (VKA): A STUDY USING EQ-5D QUESTIONNAIRE
|
Monzini, M
|
|
2005
|
8 |
Supplement 1 |
p. A116-A117
nvt p.
|
artikel
|
| 45 |
PCV16 KNOWLEDGE AND USE OF TREATMENT GUIDELINES FOR STROKE PREVENTION OF PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION (AFIB) IN GERMANY
|
Burkowitz, J
|
|
2005
|
8 |
Supplement 1 |
p. A93-
1 p.
|
artikel
|
| 46 |
PCV14 MODELING THE ECONOMIC CONSEQUENCES OF CARDIAC RESYNCHRONIZATION THERAPY IN THE UK
|
Caro, JJ
|
|
2005
|
8 |
Supplement 1 |
p. 264-265
2 p.
|
artikel
|
| 47 |
PCV65 PHARMACOECONOMIC ANALYSIS OF 160MG VALSARTAN VERSUS LOSARTAN AND TELMISARTAN IN THE TREATMENT OF SYSTEMIC ARTERIAL HYPERTENSION IN THE MEXICAN HEALTH SECTOR
|
Guzman, JA
|
|
2005
|
8 |
Supplement 1 |
p. A108-
1 p.
|
artikel
|
| 48 |
PCV51 PROJECTED LDL-C REDUCTION AND GOAL ATTAINMENT BY SWITCHING PATIENTS TO DUAL INHIBITION THERAPY (EZETIMIBE/SIMVASTATIN 10/20MG) IN SPAIN
|
Nocea, G
|
|
2005
|
8 |
Supplement 1 |
p. A104-
1 p.
|
artikel
|
| 49 |
PDB20 COMPARISON OF THE COST TO REACH A1C TARGETS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS ON ORAL ANTIDIABETIC AGENTS AND EITHER BIPHASIC INSULIN ASPART 70/30 OR INSULIN GLARGINE
|
Cobden, D
|
|
2005
|
8 |
Supplement 1 |
p. 358-
1 p.
|
artikel
|
| 50 |
PDB28 COST-EFFECTIVENESS ANALYSES OF BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR + HUMAN SOLUBLE INSULIN VERSUS NEUTRAL PROTAMINE HAGEDORM + HUMAN SOLUBLE INSULIN REGIMENS IN GERMANY
|
Valentine, WJ
|
|
2005
|
8 |
Supplement 1 |
p. A163-
1 p.
|
artikel
|
| 51 |
PDB21 COST-EFFECTIVENESS ANALYSIS OF BASAL/BOLUS THERAPY IN TYPE-1 DIABETES USING INSULIN DETEMIR + INSULIN ASPART OR HUMAN SOLUBLE INSULIN-BASED BASAL/BOLUS REGIMENS IN GERMANY
|
Valentine, WJ
|
|
2005
|
8 |
Supplement 1 |
p. A160-A161
nvt p.
|
artikel
|
| 52 |
PDB18 COST-EFFECTIVENESS OF ADD-ON PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) THERAPY IN DIABETIC VERSUS NON-DIABETIC PATIENTS WITH DYSLIPIDEMIA: A UK PERSPECTIVE
|
Paschen, B
|
|
2005
|
8 |
Supplement 1 |
p. A159-A160
nvt p.
|
artikel
|
| 53 |
PDB1 DIABETIC PERIPHERAL NEUROPATHY: EVALUATION OF THE INTER-ASSOCIATION BETWEEN THE RANGES OF NEUROPATHIC SYMPTOMS
|
Currie, CJ
|
|
2005
|
8 |
Supplement 1 |
p. A154-
1 p.
|
artikel
|
| 54 |
PDB3 EARLY DETECTION OF CVD BY MYOCARDIAL PERFUSION IMAGING IN ASYMPTOMATIC PATIENTS WITH DIABETES
|
Papatheofanis, FJ
|
|
2005
|
8 |
Supplement 1 |
p. 352-353
2 p.
|
artikel
|
| 55 |
PDB14 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NEUTRAL PROTAMINE HAGEDORN-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN A DUTCH SETTING
|
Roze, S
|
|
2005
|
8 |
Supplement 1 |
p. 356-
1 p.
|
artikel
|
| 56 |
PDB23 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN GERMANY
|
Palmer, AJ
|
|
2005
|
8 |
Supplement 1 |
p. A161-
1 p.
|
artikel
|
| 57 |
PDB19 ECONOMIC EVALUATION OF SWITCHING TYPE-1 DIABETES PATIENTS FROM LONG-ACTING INSULIN GLARGINE INA BASAL/BOLUS REGIMEN TO LONG-ACTING INSULIN DETEMIR IN AN AUSTRIAN SETTING
|
Palmer, AJ
|
|
2005
|
8 |
Supplement 1 |
p. A160-
1 p.
|
artikel
|
| 58 |
PDB37 HEALTH ECONOMIC COMPARISON OF INSULIN ASPART, A FAST-ACTING INSULIN ANALOG, VERSUS HUMAN INSULIN AS MEALTIME INSULIN IN THE TREATMENT OF TYPE-1 DIABETES IN AUSTRIAN, DANISH, DUTCH, FINNISH, FRENCH, GERMAN, NORWEGIAN, SPANISH AND SWEDISH SETTINGS
|
Palmer, AJ
|
|
2005
|
8 |
Supplement 1 |
p. 363-
1 p.
|
artikel
|
| 59 |
PDB29 HEALTH ECONOMIC EVALUATION OF INSULIN GLARGINE FOR THE TREATMENT OF TYPE-1 AND TYPE-2 DIABETES
|
Thompson, M
|
|
2005
|
8 |
Supplement 1 |
p. A163-
1 p.
|
artikel
|
| 60 |
PDB53 INTERNAL VALIDATION OF THE ECONOMIC ASSESSMENT OF GLYCEMIC CONTROL AND LONG-TERM EFFECTS (EAGLE) DIABETES MODEL
|
Walzer, S
|
|
2005
|
8 |
Supplement 1 |
p. A171-
1 p.
|
artikel
|
| 61 |
PDB22 LONG-TERM COST-EFFECTIVENESS OF INSULIN ASPART VERSUS SOLUBLE HUMAN INSULIN IN PATIENTS WITH TYPE 1 DIABETES IN THE UNITED KINGDOM
|
Minshall, ME
|
|
2005
|
8 |
Supplement 1 |
p. 358-359
2 p.
|
artikel
|
| 62 |
PDB50 MODELLING THE CLINICAL CONSEQUENCES OF RIMONABANT IN ADDITION TO DIET AND EXERCISE IN ABDOMINALLY OBESE PATIENTS WITH TYPE-2 DIABETES
|
Annemans, L
|
|
2005
|
8 |
Supplement 1 |
p. A170-
1 p.
|
artikel
|
| 63 |
PDB34 NEEDLESTICK INJURY IN NURSES CARING FOR PATIENTS WITH DIABETES
|
Pashos, CL
|
|
2005
|
8 |
Supplement 1 |
p. 362-
1 p.
|
artikel
|
| 64 |
PDB35 THE COST OF DIABETES MELLITUS IN SPAIN
|
Rubio-Terrés, C
|
|
2005
|
8 |
Supplement 1 |
p. A165-
1 p.
|
artikel
|
| 65 |
PEY6 A PUBLIC HEALTH IMPACT MODEL OF ANECORTAVE ACETATE IN WET AGE-RELATED MACULAR DEGENERATION
|
Deschaseaux-Voinet, C
|
|
2005
|
8 |
Supplement 1 |
p. A176-
1 p.
|
artikel
|
| 66 |
PEY20 IMPACT OF BEST AND WORST EYE VISUAL ACUITY ON VISION-SPECIFIC HEALTH-RELATED QUALITY OF LIFE AND UTILITY IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION
|
Maurel, F
|
|
2005
|
8 |
Supplement 1 |
p. A180-
1 p.
|
artikel
|
| 67 |
PEY3 REFILL COSTS AND BUDGET IMPACT OF GLAUCOMA LIPID THERAPY: A RETROSPECTIVE DATABASE ANALYSIS
|
Walt, JG
|
|
2005
|
8 |
Supplement 1 |
p. 368-
1 p.
|
artikel
|
| 68 |
PGI10 COST EFFECTIVENESS OF PROTON PUMP INHIBITOR TRIPLE THERAPY REGIMENS FOR HELICOBACTER PYLORI ERADICATION IN THE PRIMARY CARE SETTING IN IRELAND
|
Nagle, V
|
|
2005
|
8 |
Supplement 1 |
p. A121-
1 p.
|
artikel
|
| 69 |
PGI9 MODELING RISK OF GI EVENTS AMONG MEDICAID NSAID USERS, USING PROPENSITY SCORES
|
Shaya, FT
|
|
2005
|
8 |
Supplement 1 |
p. 372-
1 p.
|
artikel
|
| 70 |
PGI13 THE IMPACT OF GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY: A SYSTEMATIC REVIEW
|
Wahlqvist, P
|
|
2005
|
8 |
Supplement 1 |
p. A122-
1 p.
|
artikel
|
| 71 |
PGI13 USING ADVANCED SIMULATION MODELING TO EXAMINE THE IMPACT OF INCREASED RESOURCES ON PATIENT THROUGHPUT IN OUTPATIENT CARE
|
Lahue, BJ
|
|
2005
|
8 |
Supplement 1 |
p. 373-
1 p.
|
artikel
|
| 72 |
PHM4 UK COST COMPARISON OF BUCY2 CONDITIONING IN ALLOGENEIC HSCT: ORAL VERSUS IV BUSULFAN (BUSILVEX®)
|
Groves, LJ
|
|
2005
|
8 |
Supplement 1 |
p. A126-
1 p.
|
artikel
|
| 73 |
PHP11 AN INTRODUCTION TO HEALTH TOURISM AND MEDICAL TOURISM
|
Carrera, P
|
|
2005
|
8 |
Supplement 1 |
p. A184-
1 p.
|
artikel
|
| 74 |
PHP47 COST-MINIMIZATION ANALYSIS OF SEROLOGIC SCREENING POLICY OPTIONS FOR US ARMY ACCESSION IMMUNIZATIONS
|
Nevin, RL
|
|
2005
|
8 |
Supplement 1 |
p. 297-
1 p.
|
artikel
|
| 75 |
PHPI6 ADVERTISING IN RESPONSE TO NEW PRODUCT ENTRY: AN EXAMINATION OF THE STRATEGIC ROLE OF PHARMACEUTICAL ADVERTISING ON MARKET COMPETITION
|
Kwong, WJ
|
|
2005
|
8 |
Supplement 1 |
p. 287-
1 p.
|
artikel
|
| 76 |
PHPI9 MEDICATION NEEDS OF ELDERLY INDIVIDUALS WITHOUT PRESCRIPTION DRUG COVERAGE
|
Tran, BV
|
|
2005
|
8 |
Supplement 1 |
p. 288-
1 p.
|
artikel
|
| 77 |
PHP43 IMPACT OF PHARMACEUTICAL POLICIES ON PROMOTIONAL TARGETED DRUGS
|
Layton, MR
|
|
2005
|
8 |
Supplement 1 |
p. A193-A194
nvt p.
|
artikel
|
| 78 |
PHP8 RESOURCE CONSUMPTION IN PLATELET PRODUCTION FROM THE PERSPECTIVE OF A TRANSFUSION MEDICINE DEPARTMENT IN GERMANY
|
Segerer, C
|
|
2005
|
8 |
Supplement 1 |
p. A183-
1 p.
|
artikel
|
| 79 |
PHP2 THE MEDINET-PROJECT—A FEASIBILITY STUDY ON MEDICATION COMPLIANCE UNDER REAL LIFE CONDITIONS
|
Sterz, R
|
|
2005
|
8 |
Supplement 1 |
p. 283-
1 p.
|
artikel
|
| 80 |
PHP25 USING AN ITALIAN POPULATION DATABASE TO PROFILE PREVALENCE AND COSTS OF CHRONIC CONDITIONS
|
Yuen, EJ
|
|
2005
|
8 |
Supplement 1 |
p. A188-
1 p.
|
artikel
|
| 81 |
PHP33 UTILITY OF MEDIA ON HEALTH PROMOTION AND SELFMEDICATION
|
Tasic, D
|
|
2005
|
8 |
Supplement 1 |
p. 292-
1 p.
|
artikel
|
| 82 |
PIH1 COST-EFFECTIVENESS MODEL OF PALIVIZUMAB IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2005
|
8 |
Supplement 1 |
p. A52-
1 p.
|
artikel
|
| 83 |
PIHI5 IMPACT OF BENEFIT DESIGN ON PDE-5 UTILIZATION AND COSTS IN A LARGE PBM DATABASE
|
Patel, BV
|
|
2005
|
8 |
Supplement 1 |
p. 302-
1 p.
|
artikel
|
| 84 |
PIHI INCORPORATING OF HERD IMMUNITY INTO PHARMACOECONOMIC EVALUATION OF PNEUMOCOCCAL CONJUGATE VACCINE PNC-7
|
Claes, C
|
|
2005
|
8 |
Supplement 1 |
p. 298-
1 p.
|
artikel
|
| 85 |
PIH12 QUALITY OF LIFE AND HEALTH BEHAVIORS OF VENEZUELAN PHARMACY STUDENTS
|
Bastardo, YM
|
|
2005
|
8 |
Supplement 1 |
p. A55-
1 p.
|
artikel
|
| 86 |
PIN17 COST-EFFECTIVENESS ANALYSIS OF ENFUVIRTIDE ADDED TO AN OPTIMISED THERAPYVS. AN OPTIMISED THERAPY ALONE IN PATIENTS WITH H.I.V/AIDS
|
Serrano, D
|
|
2005
|
8 |
Supplement 1 |
p. A60-A61
nvt p.
|
artikel
|
| 87 |
PIN6 ECONOMIC EVALUATION OF VACCINATION AGAINST STREPTOCOCCUS PNEUMONIAE IN GERMANY INCLUDING HERD IMMUNITY EFFECTS
|
Reinert, RR
|
|
2005
|
8 |
Supplement 1 |
p. 306-
1 p.
|
artikel
|
| 88 |
PIN2 ECONOMIC IMPLICATION OF HEPATITIS B VIRAL (HBV) LOAD REDUCTION FOR ENTEVAVIR IN HEPATITIS B E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS
|
Yuan, Y
|
|
2005
|
8 |
Supplement 1 |
p. A56-
1 p.
|
artikel
|
| 89 |
PIN9 EXPLORING THE COST-EFFECTIVENESS OF AN IMMUNISATION PROGRAMME FOR ROTAVIRUS GASTROENTERITIS IN THE UNITED KINGDOM
|
Lorgelly, PK
|
|
2005
|
8 |
Supplement 1 |
p. 307-
1 p.
|
artikel
|
| 90 |
PIN19 UTILISATION OF ANTIBIOTICS WITHIN THE SLOVAK REPUBLIC
|
Tesar, T
|
|
2005
|
8 |
Supplement 1 |
p. 310-
1 p.
|
artikel
|
| 91 |
PMC31 AT WHAT COST? A REVIEW OF DRUG ACQUISITION COST ISSUES IN MODELLED ECONOMIC EVALUATIONS.
|
Wonder, M
|
|
2005
|
8 |
Supplement 1 |
p. 384-
1 p.
|
artikel
|
| 92 |
PMC1 DEVELOPMENT OF A NEW QUESTIONNAIRE TO MEASURE SATISFACTION WITH TREATMENT WITH MEDICINES (SATMED-Q)
|
Ruíz, M
|
|
2005
|
8 |
Supplement 1 |
p. A65-
1 p.
|
artikel
|
| 93 |
PMC19 HOW LONG AGO …?: ASSESSING PATIENT ADHERENCE TO SPECIFIED QUESTIONNAIRE RECALL PERIODS
|
Coyne, KS
|
|
2005
|
8 |
Supplement 1 |
p. A70-
1 p.
|
artikel
|
| 94 |
PMC4 THE CONTRIBUTION OF PREVENTION AND MEDICAL CARE TO POPULATION HEALTH
|
Meerding, WJ
|
|
2005
|
8 |
Supplement 1 |
p. A66-
1 p.
|
artikel
|
| 95 |
PMC13 VALUE OF ADDING MEDICAL CLAIMS DATA TO THE PHARMACY-BASED MODELS PREDICTING FUTURE HEALTH CARE COSTS AND JUMPS IN COSTS
|
Parsons, O
|
|
2005
|
8 |
Supplement 1 |
p. 378-
1 p.
|
artikel
|
| 96 |
PMH10 A MODELLED ECONOMIC EVALUATION COMPARING ATOMOXETINEWITH CURRENT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN THE NETHERLANDS
|
Laing, A
|
|
2005
|
8 |
Supplement 1 |
p. A198-
1 p.
|
artikel
|
| 97 |
PMH42 COMPARISON OF SSRI AND SNRI TREATMENT FOR DEPRESSION IN PRIMARY CARE: A NATURALISTIC STUDY
|
Machado, M
|
|
2005
|
8 |
Supplement 1 |
p. A208-A209
nvt p.
|
artikel
|
| 98 |
PMH28 COST-EFFECTIVENESS ANALYSIS OF ZIPRASIDONE VERSUS NO TREATMENT FOR SCHIZOPHRENIA RELAPSE PREVENTION
|
Azanza, JR
|
|
2005
|
8 |
Supplement 1 |
p. A204-
1 p.
|
artikel
|
| 99 |
PMH45 COST EFFECTIVENESS OF DULOXETINE COMPARED WITH VENLAFAXINE-XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
|
Van Baardewijk, M
|
|
2005
|
8 |
Supplement 1 |
p. A209-A210
nvt p.
|
artikel
|
| 100 |
PMH14 DUTCH ADAPTION OF THE COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE MANIA IN BIPOLAR I DISORDER
|
Klok, RM
|
|
2005
|
8 |
Supplement 1 |
p. A199-A200
nvt p.
|
artikel
|
| 101 |
PMH43 IMPACT OF A PSYCHOEDUCATION PROGRAM ON HEALTH STATUS OF SEVERE AND PERSISTENTLY MENTALLY ILL
|
Bellnier, T
|
|
2005
|
8 |
Supplement 1 |
p. 397-398
2 p.
|
artikel
|
| 102 |
PMH12 PREVALANCE AND COST OF BIPOLAR DISORDER AND TREATMENT WITHIN A MANAGED CARE ORGANIZATION
|
Lew, KH
|
|
2005
|
8 |
Supplement 1 |
p. 388-
1 p.
|
artikel
|
| 103 |
PMH46 RELIABILITY AND VALIDITY OF THE READINESS FOR DISCHARGE QUESTIONNAIRE IN SCHIZOPHRENIA
|
Ruetsch, C
|
|
2005
|
8 |
Supplement 1 |
p. 398-399
2 p.
|
artikel
|
| 104 |
PMH15 STUDY GAPS IN ECONOMIC EVALUATIONS OF PHARMACOTHERAPY IN BIPOLAR DISORDER
|
Hassan, MK
|
|
2005
|
8 |
Supplement 1 |
p. 389-
1 p.
|
artikel
|
| 105 |
PMH29 THE EFFECT OF RAISING THREE TIER COPAYMENTS ON SSRI COMPLIANCE RATES
|
Bron, MS
|
|
2005
|
8 |
Supplement 1 |
p. 393-
1 p.
|
artikel
|
| 106 |
PMH60 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR: DATA QUALITY ASSURANCE GATE KEEPING METHODS
|
Farmer, D
|
|
2005
|
8 |
Supplement 1 |
p. 403-
1 p.
|
artikel
|
| 107 |
PNL12 A RETROSPECTIVE STUDY OF DRUG TREATMENT PATTERNS AMONGST UK PRIMARY CARE PATIENTS WITH RESTLESS LEGS SYNDROME (RLS) BETWEEN I ST APRIL 2004 AND 3 I ST MARCH 2005
|
Das Gupta, R
|
|
2005
|
8 |
Supplement 1 |
p. A131-A132
nvt p.
|
artikel
|
| 108 |
PNL9 COST-EFFECTIVENESS OF ALTERNATIVE POLIO IMMUNIZATION POLICIES IN SOUTH AFRICA
|
Griffiths, UK
|
|
2005
|
8 |
Supplement 1 |
p. A131-
1 p.
|
artikel
|
| 109 |
PNL19 DEVELOPMENT OF THE MULTIPLE SCLEROSIS TREATMENT SATISFACTION QUESTIONNAIRE (MSTCQ)
|
Cramer, JA
|
|
2005
|
8 |
Supplement 1 |
p. 320-
1 p.
|
artikel
|
| 110 |
PNL33 SLEEP COMPLAINTS AND DIAGNOSES IN THE NATIONAL AMBULATORY MEDICAL CARE SURVEY: 1997–2002
|
Tan, LSM
|
|
2005
|
8 |
Supplement 1 |
p. 324-
1 p.
|
artikel
|
| 111 |
PNL2 THE COST-EFFECTIVENESS OF DONEPEZILAND RIVASTIGMINE IN THE TREATMENT OF ALZHEIMER'S DISEASE IN THAILAND PRIVATE HOSPITAL
|
Pattanaprateep, O
|
|
2005
|
8 |
Supplement 1 |
p. 314-315
2 p.
|
artikel
|
| 112 |
POB5 AN ANALYSIS OF THE IMPACT OF BARIATRIC SURGERY ON HEALTH OUTCOMES AND PHARMACOLOGICAL TREATMENT AMONG OBESE PATIENTS
|
Ledoux, S
|
|
2005
|
8 |
Supplement 1 |
p. A75-
1 p.
|
artikel
|
| 113 |
POB3 PREVALENCE TRENDS OF OVERWEIGHT AND OBESITY AND TREATMENT PATTERNS FOR WEIGHT CONTROL IN THE US POPULATION
|
Valiyeva, L
|
|
2005
|
8 |
Supplement 1 |
p. 406-
1 p.
|
artikel
|
| 114 |
PO2 DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A
|
Pare, P
|
|
2005
|
8 |
Supplement 1 |
p. A8-
1 p.
|
artikel
|
| 115 |
POS4 COST-EFFECTIVENESS OF PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS WITH ALENDRONATE ORALFACALCIDOL.THE STOP-STUDY: A RANDOMIZED PLACEBO-CONTROLLED TRIAL
|
De Nijs, R
|
|
2005
|
8 |
Supplement 1 |
p. A136-
1 p.
|
artikel
|
| 116 |
PPN7 COST-EFFECTIVENESS ANALYSIS OF THE COMBINATION TRAMADOL PLUS PARACETAMOL VERSUS CODEINE PLUS PARACETAMOL FOR POSTOPERATIVE PAIN THERAPY IN THE NETHERLANDS
|
Nuijten, MJ
|
|
2005
|
8 |
Supplement 1 |
p. A141-A142
nvt p.
|
artikel
|
| 117 |
PPN4 DIFFERENTIAL COSTS OF NEUROPHATIC PAIN (NEP) MEDICAL MANAGEMENT ACCORDING TO AETIOLOGY: RESULTS OF THE REC STUDY
|
Rodríguez, M
|
|
2005
|
8 |
Supplement 1 |
p. A140-A141
nvt p.
|
artikel
|
| 118 |
PPN6 RETROSPECTIVE ANALYSIS OF DRUG UTILIZATION PATTERNS IN CANCER AND NON-CANCER PATIENTS TRANSDERMAL FENTANYL
|
Poulsen, Nautrup B
|
|
2005
|
8 |
Supplement 1 |
p. 411-412
2 p.
|
artikel
|
| 119 |
PPN3 SUMMARY OF HOSPITAL LOGISTICS ASSOCIATED WITH INTRAVENOUS PATIENT-CONTROLLED ANALGESIA (IV PCA) FOR ACUTE POSTOPERATIVE PAIN MANAGEMENT
|
Zhang, M
|
|
2005
|
8 |
Supplement 1 |
p. 410-411
2 p.
|
artikel
|
| 120 |
PR1 EVALUATION OF PREFERENCES IN GENITAL HERPES TREATMENT USING A DISCRETE CHOICE EXPERIMENT
|
Scalone, L
|
|
2005
|
8 |
Supplement 1 |
p. A18-
1 p.
|
artikel
|
| 121 |
Probabilistic Markov Model to Assess the Cost-Effectiveness of Bronchodilator Therapy in COPD Patients in Different Countries
|
Oostenbrink, Jan B.
|
|
2005
|
8 |
Supplement 1 |
p. 32-46
15 p.
|
artikel
|
| 122 |
PRS19 IMPACT OF DYSPNOEA ON DAILY ACTIVITIES IN COPD PATIENTS—DEVELOPMENT AND TESTING OF A NEW QUESTIONNAIRE FOR CLINICAL PRACTICE AND CLINICAL TRIALS
|
Arnould, B
|
|
2005
|
8 |
Supplement 1 |
p. A217-
1 p.
|
artikel
|
| 123 |
PRS5 PHARMACOECONOMIC EVALUATION OFTIOTROPIUM IN THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SPAIN
|
De Lucas, P
|
|
2005
|
8 |
Supplement 1 |
p. A212-A213
nvt p.
|
artikel
|
| 124 |
PRS15 PREDICTING EXACERBATION EVENTS IN COPD USING ADMINISTRATIVE DATA
|
Nelson, LS
|
|
2005
|
8 |
Supplement 1 |
p. 329-
1 p.
|
artikel
|
| 125 |
PRS1 PULMONOLOGISTS' PERCEPTIONS OF ANEMIA IN COPD: A SURVEY
|
Zilberberg, M
|
|
2005
|
8 |
Supplement 1 |
p. 325-
1 p.
|
artikel
|
| 126 |
PSN12 NAIL PSORIASIS: ELABORATION OF A SCALE FOR FUNCTIONAL DISCOMFORT
|
Taieb, C
|
|
2005
|
8 |
Supplement 1 |
p. A146-
1 p.
|
artikel
|
| 127 |
PSN22 SENSITIVE SKIN: IMPACT ON QUALITY OF LIFE
|
Misery, L
|
|
2005
|
8 |
Supplement 1 |
p. A149-
1 p.
|
artikel
|
| 128 |
PSR1 COST-EFFECTIVENESS OF CLOPIDOGREL VERSUS ASPIRIN IN THE PREVENTION OF ISCHEMIC EVENTS IN STROKE AND TIA PATIENTS: A FOUR-EUROPEAN COUNTRY ANALYSIS
|
Palmer, AJ
|
|
2005
|
8 |
Supplement 1 |
p. 334-
1 p.
|
artikel
|
| 129 |
PSR4 FREQUENCY OF INR TESTING IN MEDICARE BENEFICIARIES AT HIGH RISK FOR STROKE
|
Santry, B
|
|
2005
|
8 |
Supplement 1 |
p. 335-
1 p.
|
artikel
|
| 130 |
PUK24 BPH: CONSEQUENCES ON THE SPOUSE'S & PATIENT'S SEXUALITY
|
Perrin, P
|
|
2005
|
8 |
Supplement 1 |
p. A84-
1 p.
|
artikel
|
| 131 |
PUK10 COST-EFFECTIVENESS OF MIMPARAAMONG DIALYSIS PATIENTS IN BELGIUM USING A MARKOV SIMULATION MODEL
|
Roze, S
|
|
2005
|
8 |
Supplement 1 |
p. A80-
1 p.
|
artikel
|
| 132 |
PUK13 COST-MINIMISATION-ANALYSIS ON THE TREATMENT OF URINARY INCONTINENCE WITH TROSPIUM CHLORIDE IN COMPARISON WITH OXYBUTYNIN IN GERMANY
|
Heinen-Kammerer, T
|
|
2005
|
8 |
Supplement 1 |
p. A81-
1 p.
|
artikel
|
| 133 |
PUK10 EPOETIN ALFA AND DARBEPOETIN ALFA DOSING TRENDS IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS
|
Mody, S
|
|
2005
|
8 |
Supplement 1 |
p. 416-
1 p.
|
artikel
|
| 134 |
QL7 IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN
|
Prezioso, D
|
|
2005
|
8 |
Supplement 1 |
p. A13-A14
nvt p.
|
artikel
|
| 135 |
RSI QUALITY OF LIFE IN ASTHMA PATIENTS IS AFFECTED BY HOME TELEMANAGEMENT
|
Joshi, A
|
|
2005
|
8 |
Supplement 1 |
p. 246-
1 p.
|
artikel
|
| 136 |
Using Multiple Anchor- and Distribution-Based Estimates to Evaluate Clinically Meaningful Change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) Instrument
|
Yost, Kathleen J.
|
|
2005
|
8 |
Supplement 1 |
p. 117-127
11 p.
|
artikel
|
Tijdschrift beschrijving